Virginia Law Exposes Kratom's 'Opioid Secret,' Mandates Warnings

RICHMOND, VA – May 28, 2026 – In a move that challenges the narrative of kratom as a harmless wellness supplement, Virginia has enacted a landmark law that will fundamentally change how the substance is sold and perceived across the Commonwealth. Signed by Governor Spanberger on May 26, the new legislation mandates addiction warnings on all kratom products and bans the sale of its most potent opioid-like derivatives.

Effective July 1, 2026, kratom products must be kept behind the counter or in locked cases, accessible only with assistance. More significantly, they must bear a stark warning: "THIS PRODUCT MAY CAUSE DEPENDENCE AND OPIOID-LIKE WITHDRAWAL." The law, HB360, also prohibits the sale of products containing concentrated 7-hydroxymitragynine (7-OH), an alkaloid produced from kratom that is widely accepted to be more potent than morphine.

The celebratory signing ceremony was a moment of profound victory for advocates who have long warned of kratom's dangers. Standing alongside the governor was Cameron Francis, a young man who nearly lost his life and his future to the substance. Once a promising track athlete at Liberty University on the verge of breaking the four-minute mile, Cameron's life spiraled into addiction in 2017, derailing his career and consuming most of his twenties. His personal battle became the catalyst for a statewide policy shift.

A Personal Crusade Becomes Public Policy

The fight for HB360 was deeply personal. It was spearheaded by Cameron's father, Dean Francis, who founded the advocacy group End Kratom Addiction in 2025 after witnessing the devastating impact of the substance on his son and family. For years, the Francis family navigated a nightmare of addiction, health crises, and a desperate search for answers about a product marketed as a benign herbal supplement.

"This law is a victory for truth over deception," said Dean Francis, standing beside his recovering son at the governor's office. "Virginia lawmakers rejected the false 'non-addictive, harmless' narrative of the American Kratom Association and its so-called experts, as they discovered the industry's trade secret: part of kratom converts in the body to an opioid stronger than morphine."

His organization, End Kratom Addiction, provided a platform for other families and addiction specialists to share their stories. Their compelling and often heartbreaking testimony during legislative hearings painted a picture of kratom that stood in stark contrast to the industry's marketing. One clinical director described the withdrawal she regularly witnesses as "demonic," while a psychiatric nurse practitioner, Kate Gibson of Richmond's Coleman Clinic, testified that over half of her new patients were seeking help for kratom addiction, requiring medical protocols identical to those used for heroin.

Unmasking Kratom's 'Opioid Secret'

At the heart of the legislative debate was the science of kratom itself. The plant contains dozens of alkaloids, but the two most prominent are mitragynine and 7-hydroxymitragynine (7-OH). While mitragynine is more abundant, it is metabolized in the human liver into the far more potent 7-OH, which is a powerful mu-opioid receptor agonist—the same mechanism of action as morphine and heroin.

This scientific fact, long downplayed by the kratom industry, became a focal point of the hearings. In a moment of high drama, State Senator Jeremy McPike repeatedly pressed an expert representing the American Kratom Association (AKA), the industry's primary lobbying group. After asking three times, "What does kratom turn into in the liver?" the expert finally conceded that it converts into 7-hydroxymitragynine.

Advocates for the bill seized on this admission, arguing it exposed the industry's deceptive marketing. While the AKA has historically promoted a regulatory framework called the Kratom Consumer Protection Act (KCPA), critics argue their efforts have primarily focused on preventing outright bans while obscuring the substance's fundamental opioid-like nature. The recent emergence of highly concentrated 7-OH tablets, sold directly to consumers, further undermined the "natural leaf" argument and triggered a new wave of addiction and harm, prompting legislative action in Virginia and elsewhere.

A Legislative Rebuke to Industry Influence

The passage of HB360 was not a narrow victory but a powerful, bipartisan consensus. The bill, sponsored by Delegate Josh Cole, sailed through committees and floor votes with overwhelming margins, including 95-2 in the House and a unanimous 40-0 in the Senate.

"These were not narrow votes. They represent a resounding bi-partisan rebuke," said Hilary Tesluck, Executive Director of End Kratom Addiction. "Virginia chose families over lobbyists, facts over fiction, and public health over predatory commerce. Industry spin is not science and paid testimony is not truth."

The coalition supporting the bill was unusually broad, uniting the Virginia Pharmacy Association, multiple chambers of commerce including the Virginia Black Chamber and Virginia Hispanic Chamber, and numerous addiction treatment centers. This wide-ranging support demonstrated that concern over unregulated kratom had moved from the fringes to the mainstream of Virginia's medical and business communities.

Delegate Cole framed the law as a matter of consumer protection and truth in advertising. "Marketing an opioid-like substance as a harmless wellness supplement is unacceptable, especially when young people, families, and vulnerable consumers may not understand the high-stake risks," he stated. "If this law helps even one person understand how risky kratom can be, and how addictive it can become, then I believe we have done the right thing."

Virginia's Law in a National Patchwork

Virginia's new regulations place it at the forefront of a complex and evolving national landscape. A handful of states, including Alabama, Arkansas, and Indiana, have banned kratom entirely. In contrast, more than a dozen states have adopted versions of the industry-backed KCPA, which focuses on age limits and labeling without the stringent 7-OH ban or explicit opioid-like withdrawal warnings now required in Virginia.

Virginia's hybrid approach—regulating the base product while banning its most dangerous iteration and mandating clear, potent warnings—could serve as a new model for states grappling with the issue. By directly confronting the science of 7-OH and the reality of physical dependence, the law moves beyond the simple regulate-or-ban dichotomy that has defined the kratom debate for years.

For advocates like Dean Francis, the victory in Virginia is just one step in a larger battle. He sees the law as a clear message to the industry that its long-standing tactics will no longer work. "Your playbook of deception was exposed," Francis declared. "Your narrative was rejected. The truth has been revealed."